Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

LLY stock is gaining positive traction. See the full story here

The U.S. weight loss drug giant reported quarterly revenue of $17.60 billion, up 54% year over year, beating the consensus of $16.02 billion, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices.

Key Products revenue grew to $11.98 billion in Q3 2025, led by Mounjaro and Zepbound.

The company reported an adjusted earnings per share of $7.02, a sharp jump from $1.18 a year ago, beating the consensus of $5.70.

Also Read: Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart

Weightloss ...